We tested the new orally active nonpeptidic << renin >> inhibitor SPP100 (Aliskiren, an [[ octanamide ]] with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.